Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23682669 | 0.81 | GFER (0.36) | GFERCDK2CDK1CDK3CCNA2 | |
| SCHEMBL23815751 | 0.76 | GFER (0.36) | GFERCDK2CDK1CDK3CCNA2 | |
| SCHEMBL6842163 | 0.67 | KMT2A (0.48) | GFERCDK2CCNA2L3MBTL1ALDH1A1 | |
| SCHEMBL26546527 | 0.66 | CDK2 (0.38) | CDK2CCNA2ALDH1A1 | |
| SCHEMBL23815725 | 0.65 | SHMT2 (0.39) | CDK2CCNA2L3MBTL1ALDH1A1 | |
| SCHEMBL2880579 | 0.65 | COPS5 (0.35) | — | |
| SCHEMBL27624142 | 0.65 | KMT2A (0.42) | GFERCDK2CCNA2L3MBTL1ALDH1A1 | |
| SCHEMBL25697068 | 0.64 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2878486 | 0.62 | TNIK (0.49) | CDK2CCNA2ALDH1A1 | |
| SCHEMBL14820153 | 0.61 | NPSR1 (0.42) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | GFER 3523/4885CDK2 588/4885CDK1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.